腾药Tengyao品牌怎么样 申请店铺

我要投票 腾药Tengyao在乌鸡白凤丸行业中的票数:226 更新时间:2025-02-05
腾药Tengyao是哪个国家的品牌?「腾药Tengyao」是 云南腾药制药股份有限公司 旗下著名品牌。该品牌发源于云南省保山市,由创始人赵丙贤在1990-06-22期间创立,经过多年的不懈努力和高速发展,现已成为行业的标杆品牌。
腾药Tengyao怎么样

云南腾药制药股份有限公司(以下简称“腾药”)成立于1956年,1997年改为股份合作制企业,2011年9月在县委政府的关心支持下完成股份制改造,同年11月与北京中证万融医药投资集团实现战略合作。

历经五十多年历史积淀的腾药,目前在编在岗员工600余人(含销售人员),具备了雄厚的制药技术基础,公司在不断汲取现代科学技术的基础上具备了专业的检测手段。两者的有机结合,使“腾药”产品有了过硬的质量,造就的品种有心脉隆注射液、安宫牛黄丸、人参再造丸、六味地黄丸、六灵丸、藿香正气水、感冒疏风片、清肺抑火片等。年生产规模为2000多吨,主要剂型有注射剂、丸剂(大蜜丸、小蜜丸、水丸、水蜜丸)、片剂、颗粒剂、散剂、酒剂、酊剂、糖浆剂,国药准字批文 130个,87个品种,137个品规,均是中药、天然药物。其中,国家二类新药“心脉隆注射液”由企业与大理学院联合研制,于2007年获准生产上市,为腾药的发展注入了新的活力。

规划:发展为以心脉隆注射液为主,传统普药为辅,日化保健品为补的上市企业。

党建:公司党总支下设5个党支部,共有党员62名(其中女党员37名)。

文化:公司起源于药王宫(建于明代天启六年)——全国中医药文化宣传教育基地,整个以求健康、传健康、学健康、食健康为主。公司秉承诚信制药,争做百年腾药。公司核心使命:“为人类健康创造卓越价值”,核心价值:“顾客第一服务他人 诚信 创新”。

诚信:公司一直秉承诚信制药的优良传承,用“宁为上药三分利,莫负良医九折肱”的对联警醒着一代又一代制药人。

创新:以心脉隆注射液为主的科研课题研究、美蠊系列日化保健品开发。


Yunnan tengyao Pharmaceutical Co., Ltd. (hereinafter referred to as "tengyao") was founded in 1956, changed into a joint-stock cooperative enterprise in 1997, completed the joint-stock transformation in September 2011 with the care and support of the county Party committee and government, and achieved strategic cooperation with Beijing Zhongzheng Wanrong pharmaceutical investment group in November of the same year. After more than 50 years of historical accumulation, tengyao has more than 600 employees (including sales staff) on the job at present, with a strong pharmaceutical technology foundation, and the company has a professional testing method based on continuous learning of modern science and technology. The organic combination of the two makes the "tengyao" products have excellent quality. The varieties created are Xinmailong injection, Angongniuhuang pill, Renshen Zaizai pill, Liuwei Dihuang pill, Liuling pill, Huoxiang Zhengqi water, Ganmao Shufeng tablet, Qingfei Yihuo tablet, etc. The annual production scale is more than 2000 tons, and the main dosage forms are injection, pill (big honey pill, small honey pill, water pill, water honey pill), tablet, granule, powder, liquor, tincture, syrup. There are 130 national drug approval documents, 87 varieties, 137 product specifications, all of which are traditional Chinese medicine and natural medicine. Among them, Xinmailong injection, a national second-class new drug, was jointly developed by the enterprise and Dali University, and was approved for production and listing in 2007, which injected new vitality into the development of tengyao. Planning: to develop into a listed enterprise mainly with Xinmailong injection, supplemented by traditional general medicine and supplemented by daily chemical health products. Party Construction: the company has 5 party branches under the general Party branch, with 62 party members (including 37 female party members). Culture: the company originated in the palace of Medicine (built in the sixth year of Tianqi in Ming Dynasty) - the national base of traditional Chinese medicine culture publicity and education, focusing on health, transmission, learning and eating. The company adheres to the integrity of pharmaceutical, striving to be a century drug. The company's core mission: "to create outstanding value for human health", and its core value: "customer first, serve others and innovate with integrity". Integrity: the company has always been adhering to the good heritage of integrity pharmaceutical, with the couplet of "better for the third profit of the drug, better for the nine fold arm" to alert generations of pharmaceutical people. Innovation: Research on Xinmailong injection as the main scientific research topic, and development of Periplaneta americana series of daily chemical health products.

本文链接: https://brand.waitui.com/19813d252.html 联系电话:08755133464

千城特选小程序码

7×24h 快讯

房地产融资协调机制工作专班有关负责人:目前万科房地产项目建设正在平稳有序推进中

房地产融资协调机制工作专班有关负责人表示,从专班掌握的情况看,2024年,万科交付住房超过18万套,全面完成保交房目标任务。从各地城市房地产融资协调机制工作专班了解的情况看,目前万科房地产项目建设正在平稳有序推进中,“白名单”制度将提供有力的融资支持,充分保障项目建设交付。(中国建设报)

48分钟前

迪士尼第一财季营收247亿美元,同比增长5%

2月5日,华特迪士尼公司发布截至2024年12月28日的2025财年第一季度业绩:营收为247亿美元,同比增长5%;摊薄后每股收益为1.40美元,同比增长35%。(界面)

48分钟前

李强:锚定发展目标因时因势加大逆周期调节力度,聚焦突出问题整合资源集中发力

国务院总理李强2月5日主持召开国务院第七次全体会议。李强指出,要系统化创造性地抓好落实。既要注重整体把握,综合平衡好国内和国外、当前和长远、宏观和微观、发展和安全等关系,在多重目标中找到有效路径,也要寻求突破突围,找准潜力足、空间大的发展领域,谋划好牵引性强、撬动性强的工作抓手,打造更多能够带动全局的突出亮点。要认真总结和丰富拓展工作中探索的好做法,锚定发展目标因时因势加大逆周期调节力度,聚焦突出问题整合资源集中发力,敢于打破常规推出可感可及的政策举措,及时回应关切加强政策与市场的互动。(新华社)

48分钟前

李强:采取有力举措在做强国内大循环、推动科技创新、促进产业升级等重点领域实现新突破

国务院总理李强2月5日主持召开国务院第七次全体会议。李强强调,要以更加强烈的担当、更加积极的作为推动高质量发展取得新成效。要坚定信心、知难共进,客观辩证看待外部形势变化,统筹解决国内经济问题和应对外部挑战,变压力为动力,采取有力举措在做强国内大循环、推动科技创新、促进产业升级等重点领域实现新突破,并着眼长远打造我国发展新优势。(新华社)

48分钟前

杭钢股份:公司与DeepSeek系统的开发、应用等核心技术无关

36氪获悉,杭钢股份公告,公司关注到媒体有关于子公司DeepSeek部署适配的相关报道,公司主营业务为钢铁及其压延产品的生产和销售。钢铁及相关业务营业收入占比超过总额的90%。短期内,公司主营业务不会发生变化。相关媒体报道中涉及的DeepSeek部署适配是指,在上述业务模式下,公司在合作伙伴的系统中安装DeepSeek软件,安装后将算力设备对外提供租赁服务。公司与DeepSeek系统的开发、应用等核心技术无关,且与杭州深度求索人工智能基础技术研究有限公司无任何业务往来。

48分钟前

本页详细列出关于中联的品牌信息,含品牌所属公司介绍,中联所处行业的品牌地位及优势。
咨询